Clinical and isolate details for the patient cohort

Infection type and patient no.Age (yr)aGenderComorbidity(ies)bNo. of isolatesPresumptive source of infection by episodecYear of first isolateNo. of days between episodesNo. of SNPs between episodesdInterpretation
1st2nd3rd1st to 2nd2nd to 3rd1st to 2nd2nd to 3rd1st to 3rd
    250MaleHM, SCT2MT/IVMT/IV20071,578234Reinfection
    4e24FemaleCongenital neutropenia3IVMT/IVMT/IV20121081687311309Relapse/reinfection
    544FemaleSOT, ESRD, DM2IVUnknown2009777299Reinfection
    642FemaleAlcoholic liver disease2IVIV2009215282Reinfection
    713MaleHM, SCT, ESRD2MT/IVIV20071,484232Reinfection
    841FemaleHM, SCT, ESRD2MT/IVMT/IV20115764Reinfection
Mixed VREfm-VSEfm
    1359FemaleSOM, HM2IV20122329Genetically distinct
    1472MaleSOM, HM2MT20120119Genetically distinct
    1562MaleHM, SCT2IV20110217Genetically distinct
    1650MaleHM, SCT2MT/IV200900Genetically related
    1756MaleHM2IV2008018Genetically distinct
    1859MaleSOM2IA (biliary)20080381Genetically distinct
    1963MaleHM, SOT2IV20091203Genetically distinct
    2019MaleHM, SCT2MT/IV20100154Genetically distinct
    2148FemaleESRD, LC2Lung, IA201000Genetically related
  • a Age at the time of first bacteremia.

  • b Comorbidities identified across all episodes of bacteremia in the study (see Data set S1 in the supplemental material for a breakdown by bacteremic episode). SOM, solid organ malignancy; HM, hematological malignancy; SCT, stem cell transplant; SOT, solid organ transplant; ESRD, end stage renal disease; DM, diabetes mellitus; LC, liver cirrhosis.

  • c MT, mucosal translocation; IV, intravascular; IA, intra-abdominal; MT/IV, mucosal translocation with possible concurrent intravascular catheter infection.

  • d Number of SNPs based on mapping to a reference genome (E. faecium Aus0004).

  • e Patients with a recurrence with a different strain for whom a central venous catheter was retained between episodes of bacteremia.